{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:00:09Z","timestamp":1773910809219,"version":"3.50.1"},"reference-count":19,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MI-Kickstart","award":["9773"],"award-info":[{"award-number":["9773"]}]},{"name":"MI-Kickstart","award":["23-2250890"],"award-info":[{"award-number":["23-2250890"]}]},{"DOI":"10.13039\/100007159","name":"state of Michigan","doi-asserted-by":"publisher","award":["9773"],"award-info":[{"award-number":["9773"]}],"id":[{"id":"10.13039\/100007159","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007159","name":"state of Michigan","doi-asserted-by":"publisher","award":["23-2250890"],"award-info":[{"award-number":["23-2250890"]}],"id":[{"id":"10.13039\/100007159","id-type":"DOI","asserted-by":"publisher"}]},{"name":"department of biological sciences by Mike and Camille Monaco","award":["9773"],"award-info":[{"award-number":["9773"]}]},{"name":"department of biological sciences by Mike and Camille Monaco","award":["23-2250890"],"award-info":[{"award-number":["23-2250890"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Human melanoma is the most aggressive form of skin cancer and is responsible for the most deaths of all skin cancers. Localized tumors, and those which have limited spread, have 5-year survival rates of over 90%, with those numbers steadily rising over the past decade. However, metastatic melanomas have a sharp decrease in 5-year survival rates and are still an area of need for new, successful therapies. Immuno-oncolytic viruses (OVs) have emerged as a promising class of immunovirotherapy that can potentially address this disease. The Food and Drug Administration in the United States has approved one oncolytic herpes simplex virus expressing granulocyte-macrophage colony-stimulating factor (Talimogene Laherparepvec) for the treatment of metastatic melanoma, and others could soon follow for this and other cancers. In previous studies, Tanapoxvirus (TPV) recombinants expressing mouse interleukin-2 (mIL-2) and another expressing bacterial flagellin from Salmonella typhimurium (FliC) have demonstrated anti-tumor efficacy in nude mouse models. TPV replicates only in humans and monkeys, including tumor cells, which makes the use of syngeneic tumor models impossible for the study of this OV in a standard immunocompetent system. In this study, TPV\/\u039466R\/mIL-2 and TPV\/\u03942L\/\u039466R\/FliC were tested for their ability to treat human melanoma xenografts (SK-MEL3) in a BALB\/c nude mouse model reconstituted with splenocytes from genetically compatible, normal BALB\/c donor mice. Two SK-MEL3 tumors were transplanted into each flank of BALB\/c nude mice, and the larger tumor was treated intratumorally (IT) with virus or mock injection. In one set of animals, mice received adoptive transfers of splenocytes from BALB\/c mice on day 4 to reconstitute their immune systems and allow for adaptive immune responses to occur in a xenograft model. Direct IT injection of TPV\/\u039466R\/mIL-2 led to significantly greater rates of tumor regression compared to reconstituted control (RC) mice in the primary and distant tumor sites, whereas TPV\/\u03942L\/\u039466R\/FliC treatment led to significantly greater rates of tumor regression in distant tumor sites only. A second experiment used TPV\/\u039466R\/mIL-2 to test whether TPV could be administered intravenously (IV), intramuscularly (IM), or both routes simultaneously to exert similar anti-tumor effects in an indirectly treated tumor. A single SK-MEL3 tumor was transplanted into one flank of BALB\/c nude mice and was treated either into the tail vein, the nearest rear leg to the tumor, or both. All mice then received adoptive transfers of splenocytes in the same way as previously described on day 4 and received an additional TPV treatment on day 14. The results demonstrated that TPV\/\u039466R\/mIL-2 treatment IV or IM had significantly greater rates of tumor regression than RC-treated mice but failed to exert this effect when both routes were used simultaneously. Data obtained through these experiments support the continued development of Tanapoxvirus for the treatment of human melanoma and using immune reconstitution to create intact adaptive immunity in a xenograft context, which can allow other tropism-limited OVs to be studied against human cancers.<\/jats:p>","DOI":"10.3390\/genes14081533","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T01:56:16Z","timestamp":1690509376000},"page":"1533","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Multiple Administration Routes, Including Intramuscular Injection, of Oncolytic Tanapoxvirus Variants Significantly Regress Human Melanoma Xenografts in BALB\/c Nude Mice Reconstituted with Splenocytes from Normal BALB\/c Donors"],"prefix":"10.3390","volume":"14","author":[{"given":"Michael L.","family":"Monaco","sequence":"first","affiliation":[{"name":"Laboratory of Virology, Department of Biological Sciences, Western Michigan University, Kalamazoo, MI 49008, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer A.","family":"Idris","sequence":"additional","affiliation":[{"name":"Laboratory of Virology, Department of Biological Sciences, Western Michigan University, Kalamazoo, MI 49008, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace A.","family":"Filpi","sequence":"additional","affiliation":[{"name":"Laboratory of Virology, Department of Biological Sciences, Western Michigan University, Kalamazoo, MI 49008, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven L.","family":"Kohler","sequence":"additional","affiliation":[{"name":"Laboratory of Virology, Department of Biological Sciences, Western Michigan University, Kalamazoo, MI 49008, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Haller","sequence":"additional","affiliation":[{"name":"Charles River Laboratories, Mattawan, MI 49071, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffery E.","family":"Burr","sequence":"additional","affiliation":[{"name":"PharmOptima LLC, Portage, MI 49065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Eversole","sequence":"additional","affiliation":[{"name":"Laboratory of Virology, Department of Biological Sciences, Western Michigan University, Kalamazoo, MI 49008, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Essani","sequence":"additional","affiliation":[{"name":"Laboratory of Virology, Department of Biological Sciences, Western Michigan University, Kalamazoo, MI 49008, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"ref_1","unstructured":"American Cancer Society (2023, May 26). Cancer-Facts-and-Figures 2023. Available online: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/2023-cancer-facts-figures.html."},{"key":"ref_2","unstructured":"National Cancer Institute (2023, May 26). PDQ\u00ae Adult Treatment Editorial Board. PDQ Melanoma Treatment, Available online: https:\/\/www.cancer.gov\/types\/skin\/patient\/melanoma-treatment-pdq."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2174\/1568009617666170630143931","article-title":"Oncolytic Tanapoxvirus Expressing Interleukin-2 is Capable of Inducing the Regression of Human Melanoma Tumors in the Absence of T Cells","volume":"18","author":"Zhang","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11262-016-1402-2","article-title":"Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice","volume":"53","author":"Zhang","year":"2018","journal-title":"Virus Genes"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13046-015-0131-z","article-title":"Oncolytic Tanapoxvirus Expressing FliC Causes Regression of Human Colorectal Cancer Xenografts in Nude Mice","volume":"34","author":"Conrad","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_6","first-page":"1068","article-title":"Colorectal cancer xenografts regressed by a FliC expressing Tanapoxvirus in an immunologically reconstituted model","volume":"2","author":"Kana","year":"2022","journal-title":"Jpn. J. Gastroenterol. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1158\/0008-5472.CAN-10-1993","article-title":"Activation of toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth","volume":"71","author":"Cai","year":"2011","journal-title":"Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1158\/0008-5472.CAN-12-0337","article-title":"Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4","volume":"72","author":"Srivastava","year":"2012","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fonc.2020.00475","article-title":"Delivery and Biosafety of Oncolytic Virotherapy","volume":"10","author":"Li","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Tang, G., Wang, D., Zhao, X., Feng, Z., Chen, Q., and Shen, Y. (2023). The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043681"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/sj.mt.6300020","article-title":"Infected cell carriers: A new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy","volume":"15","author":"Iankov","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12032-017-0973-7","article-title":"T-independent response mediated by oncolytic tanapoxvirus recombinants expressing interleukin-2 and monocyte chemoattractant protein-1 suppresses human triple negative breast tumors","volume":"34","author":"Suryawanashi","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1139\/w98-212","article-title":"The replication cycle of tanapox virus in owl monkey kidney cells","volume":"45","author":"Mediratta","year":"1999","journal-title":"Can. J. Microbiol."},{"key":"ref_14","unstructured":"Everitt, B.S. (2021). Multivariable Modeling and Multivariate Analysis for the Behavioral Sciences, Springer."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Mirman, D. (2017). Growth Curve Analysis and Visualization Using R, CRC Press.","DOI":"10.1201\/9781315373218"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e1163462","DOI":"10.1080\/2162402X.2016.1163462","article-title":"Role of IL-2 in cancer immunotherapy","volume":"5","author":"Jiang","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100122","DOI":"10.1016\/j.medidd.2022.100122","article-title":"The critical role of Toll-like receptor-mediated signaling in cancer immunotherapy","volume":"14","author":"Chen","year":"2022","journal-title":"Med. Drug Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s42003-022-04403-8","article-title":"TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy","volume":"6","author":"Gonzalez","year":"2023","journal-title":"Commun. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/mt.2013.249","article-title":"Maraba virus as a potent oncolytic vaccine vector","volume":"22","author":"Pol","year":"2014","journal-title":"Mol. Ther."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/8\/1533\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:20:27Z","timestamp":1760127627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/8\/1533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":19,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["genes14081533"],"URL":"https:\/\/doi.org\/10.3390\/genes14081533","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]}}}